Gilead Sciences (<a>NASDAQ:GILD</a>) Second Quarter 2025 Results\n\nKey Financial Results\n- Revenue: US$7.08b (up 1.8% from 2Q 2024).\n- Net income: US$1.96b (up 21% from 2Q 2024).\n- Profit margin: 28% (up from 23% in 2Q 2024).\n- EPS: US$1.57 (up from US$1.29 in 2Q 2024).\n\nGilead Sciences Revenues and Earnings Beat Expectations\n- Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 5.0%.\n- Looking ahead, revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.\n- The company's shares are up 5.5% from a week ago.\n\nRisk Analysis\n- You should learn about the <a>2 warning signs we've spotted with Gilead Sciences</a>.

Gilead Sciences Second Quarter 2025 Earnings: Beats Expectations

Gilead Sciences reported stronger-than-expected financial results for its second quarter of 2025, with revenue of $7.08 billion, a 1.8% increase from the previous year, and net income of $1.96 billion, up 21% year-over-year. The company's profit margin improved to 28% from 23% in the prior quarter, and earnings per share rose to $1.57 from $1.29. Revenue outperformed analyst estimates by 1.7%, and EPS exceeded expectations by 5.0%. Analysts project average annual revenue growth of 4.0% over the next three years, compared to a 19% industry-wide growth forecast for U.S. biotech firms. The company's stock rose 5.5% from the previous week.